Lifeline Biotechnologies Prepares to Update Pink Sheets

Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that it will update Pink Sheets with current information on the Company and plans to utilize Pink Sheets’ Guidelines for maintaining the information on a current basis.

Jim Holmes, Lifeline’s CEO said that “Lifeline’s information on Pink Sheets has not been recently updated. This may take us several weeks, possibly closer to a month to complete. In particular, the financial information will be time consuming, but it will be completed as soon as possible.”

Holmes continues, “The First Warning System™, a process that has been designed, developed and tested to assist in the early detection of breast cancer, is nearly ready for submission to the FDA. The FDA’s response to this initial filing could take several months to receive. We expect the FDA’s response to give us guidance for the subsequent filing required in order to obtain marketing clearance for this proprietary process.”

Lifeline Biotechnologies previously received two patents on its First Warning System™ hardware and has in the past year filed for a patent on the technological advancements of the First Warning System ™ software. The software has achieved the robust capability of identifying and classifying tissue abnormalities of the breast with sensitivities (ability to identify) of 95% to 100% and specificities (verify) of 87% to 90%. Currently, it is widely recognized that mammograms miss an estimated 20 to 30% of the breast cancers.

Lifeline competes in the money markets for funds to continue the development of its products as well as operating and administrative expenses. The cost of funds for companies such as Lifeline is expensive and the terms have been and may continue to be dilutive.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.